Myriad Genetics (MYGN) EBITDA Margin (2009 - 2026)
Myriad Genetics (MYGN) posted quarterly EBITDA Margin of 15.32% for Q1 2026, down 52.0% year-over-year from 31.92% in Q1 2025, and down 463.86% quarter-over-quarter from 2.72% in Q4 2025.
Myriad Genetics (MYGN) EBITDA Margin (2009 - 2026) Analysis & Trends
Myriad Genetics (MYGN) has reported EBITDA Margin for 18 consecutive years, with 15.32% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 52.0% year-over-year to 15.32%; the TTM figure through Mar 2026 stood at 46.91% (down 3194.0% YoY), while the FY2025 annual figure was 46.96%, down 3222.0% from the prior year.
- EBITDA Margin declined to 15.32% in Q1 2026 per MYGN's latest filing, from 2.72% in the prior quarter.
- Across five years, EBITDA Margin topped out at 2.72% in Q4 2025 and bottomed at 154.48% in Q2 2025.
- Historically, EBITDA Margin has averaged 28.19% across 5 years, with a median of 15.97% in 2023.
- Annual changes were most pronounced in 2024 — EBITDA Margin surged 4470 bps — and 2025, when it plunged 13722 bps.
- Myriad Genetics' EBITDA Margin stood at 29.36% in 2022, then surged by 46 bps to 15.97% in 2023, then slipped by 16 bps to 18.52% in 2024, then surged by 85 bps to 2.72% in 2025, then plunged by 464 bps to 15.32% in 2026.
- Business Quant data shows MYGN's EBITDA Margin at 15.32% in Q1 2026, 2.72% in Q4 2025, and 11.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 17.40% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 17.99% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 34.98% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 21.74% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 11.58% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -13.42% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 21.14% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 31.97% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 15.08% |
| 10 | Myriad Genetics | 297.97 Mn | 173.57 Mn | 137.60 Mn | -15.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.32% |
| Dec 31, 2025 | -2.72% |
| Sep 30, 2025 | -11.33% |
| Jun 30, 2025 | -154.48% |
| Mar 31, 2025 | -14.80% |
| Dec 31, 2024 | -18.52% |
| Sep 30, 2024 | -9.38% |
| Jun 30, 2024 | -17.26% |
| Mar 31, 2024 | -13.80% |
| Dec 31, 2023 | -15.97% |
| Sep 30, 2023 | -31.32% |
| Jun 30, 2023 | -61.96% |
| Mar 31, 2023 | -28.81% |
| Dec 31, 2022 | -29.36% |
| Sep 30, 2022 | -28.77% |
| Jun 30, 2022 | -9.93% |
| Mar 31, 2022 | -15.52% |
| Dec 31, 2021 | -26.80% |
| Sep 30, 2021 | -47.76% |
| Jun 30, 2021 | -10.98% |